The human hepatic cytochromes p450 involved in drug metabolism

Critical Reviews in Toxicology

Volumn 22, Issue 1, 1992, Pages 1-21

  Wrighton, Steven A ^a   Stevens, Jeffrey C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cytochromes P450; Drug metabolism; Expression of the P450s; Human; Inhibition of the P450s; Liver; Microsomal; Mixed function oxidases; Regulation of the P450s

Indexed keywords

BUFURALOL; CAFFEINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DEXTROMETHORPHAN; DIAZEPAM; DISULFIRAM; DRUG; ENCAINIDE; FLECAINIDE; HEXOBARBITAL; IMIPRAMINE; ISONIAZID; MEPHENYTOIN; METHYLPHENOBARBITAL; METOPROLOL; MEXILETINE; MIXED FUNCTION OXIDASE; NORTRIPTYLINE; OMEPRAZOLE; PERHEXILINE; PHENACETIN; PHENOBARBITAL; PROPRANOLOL; RETINOIC ACID; RIFAMPICIN; SPARTEINE; SULFAPHENAZOLE; SULFINPYRAZONE; TIENILIC ACID; TIMOLOL; TOLBUTAMIDE;

DRUG METABOLISM; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; HUMAN; ISOENZYMES; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 0026750647     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408449209145319     Document Type: Article

References (174)

1. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature
2. Enzymatic oxidation of xeno-biotic chemicals
3. Human P-450 genes: evolution, regulation and possible role in carcinogenesis
4. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy
5. Purification and characterization of hepatic microsomal cytochrome P-450
6. Animal and plant cytochrome P-450 systems
7. Microbial cytochromes P-450 and xenobiotic metabolism
8. Characterization of human microsomal cytochrome P-450 enzymes
9. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16a-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin
10. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in
11. The molecular biology of cytochrome P450s
12. P450 genes: structure, evolution, and regulation
13. Species differences in metabolism and pharmacokinetics: are we close to an understanding?
14. The molecular biology of cytochrome P450s
15. Human dioxin-inducible cytochrome P.-450: complementary DNA and amino acid sequence
16. Human cytochrome P-450 4 mRNA and gene: part of a multigene family that containsAlu sequences in its mRNA
17. Localization of regulator elements responsible for drug induction in the rat cytochrome P-450c gene
18. Induced synthesis of liver microsomal enzymes which metabolize foreign compounds
19. Regulation of the mammalian cytochrome P. 450 (CYP1A1) gene
20. The regulation of gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin
21. Identification of a human liver cytochrome P-450 homologous to the major iso-safrole-inducible cytochrome P-450 in the rat
22. The human cytochrome CyplA2 gene contains regulatory elements responsive to 3-methylcholanthrene
23. Immunohistochemical detection of human placental cytochrome P-450-asso-ciated mono-oxygenase systeminducible by maternal cigarette smoking
24. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene
25. Human CYP1A1 gene: cosegrega-tion of the enzyme inducibility phenotype and an RFLP
26. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
27. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primary responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
28. Comparison levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal disease states using immunochemical analysis of surgical liver samples
29. Caffeine as a metabolite probe: exploration of the enzyme-inducing effect of cigarette smoking
30. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking
31. Human cytochromes P-450
32. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli, and exercise, in
33. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
34. Omeprazole treatment does not affect the metabolism of caffeine
35. Induction of estradiol metabolism by dietary indole-3-carbinol in humans
36. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol
37. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver
38. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
39. Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphen-yls, phenobarbital, and 3-methylcholanthrene
40. Purification of two isozymes of rat liver microsomal cytochrome P450 with testosterone 7a-hy-droxylation activity
41. Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene
42. The structure and characterization of type I P-450,15α gene as major steroid 15ot-hydroxylase and its comparison with type II P-45015n gene
43. Two steroid 15a-hydroxylase genes and a homologous gene family in mice
44. Mouse liver testosterone 15a-hydroxylase (cytochrome P-450,15α)
45. Mouse steroid 15α -hydroxylase gene family: identification of type II P-450,15α as coumarin 7-hydrox-ylase
46. Posttranscriptional regulation of coumarin 7-hydroxylase induction by xe-nobiotics in mouse liver: mRNA stabilization by pyr-azole
47. Identification of a polymorph-ically expressed member of the human cytochrome P-450III family
48. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse
49. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
50. Purification and characterization of human liver microsomal cytochrome P-450 2A6
51. Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1
52. Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLJ
53. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
54. Genes for cytochrome P-450 and their regulation
55. Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B-naphthoflavone
56. Identification of human cytochromes P-450 analogous to forms induced by phenobarbital and 3-methylcholanthrene in the rat
57. Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies
58. CDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver
59. A novel human cytochrome P450 gene (P450IIB): chromosomal localization and evidence for alternative splicing
60. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase
61. Identification of rabbit microsomal cytochrome P-450 isozyme, form 1, as a hepatic progesterone 21-hydroxylase
62. Characterization of multiple human cytochrome P-450 1 cDNAs
63. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats
64. Metabolism of retinal and retinoic acid by human liver cytochrome P450IIC8
65. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
66. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism
67. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system
68. Tolbutamide and mephenytoin hy-droxylation by human cytochrome P450s in the CYP2C subfamily
69. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes
70. Vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, suphonamides and quinolines
71. Tolbutamide hydroxylation by human liver microsomes
72. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis
73. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug
74. Genetic polymorphism of human cytochrome P-450 (S)-mephen-ytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency
75. Genetics of drug transformation
76. Polymorphism of cytochrome P-450 in humans
77. Polymorphic drug metabolism
78. Genetic polymorphisms of drug metabolism
79. Vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme
80. Pharmacogenetic association between the formation of 4-hydroxyme-phenytoin and a new metabolite of S-mephenytoin in man
81. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin
82. Mephenytoin hydroxylase activity in human liver: inhibition by steroids
83. Polymorphic hydroxylation of debrisoquine in man
84. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
85. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations
86. Purification and characterization of the rat microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism
87. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme
88. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man
89. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of CYP2D locus to chromosome 22
90. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
91. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes
92. Debrisoquine/ sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population
93. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino acid sequence
94. Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4
95. Two mutant alleles of the human cytochrome P-450dbl gene (P4502D1) associated with genetically deficient metabolism of debrisoquine and other drugs
96. Genetic polymorphisms of drug metabolism
97. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification
98. Relevance of genetic polymorphism in drug metabolism in the development of new drugs
99. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
100. Pharmacokinetics and analgesia of codeine and its metabolite morphine, in
101. Impact of genetic and environmental factors in codeine analgesia [Abstr.]
102. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydrox-ylation (cytochrome P-450dbl/bufl)
103. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation
104. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of im-munoidentified cytochrome P-450IID1
105. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine
106. The ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
107. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus
108. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer
109. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype
110. Debrisoquine metabolism and genetic predisposition to cancer
111. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair
112. Debrisoquine oxidation phenotype and susceptibility to lung cancer
113. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls
114. Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type II
115. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450dbl
116. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
117. Cytochrome P450IIE1: roles in nitrosa-mine metabolism and mechanisms of regulation
118. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid
119. Acetone-inducible cytochrome P-450: purification, catalytic activity, and interaction with cytochrome b5
120. Characterization of ethanol-inducible human liver N-nitrosodimethylamine de-methylase
121. Purification and characterization of human liver cytochrome P-450-ALC
122. Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity
123. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2
124. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
125. Hydrox-ylation of chlorzoxazone as a specific probe for human liver cytochrome P-450HE1
126. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives
127. Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine de-methylase, in rat hepatic microsomes
128. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s
129. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake
130. Induction and tissue-specific expression of rabbit cytochrome P450IIE1 and IIE2 genes
131. Differences in the developmental expression of rabbit cytochromes P-450 2E1 and 2E2
132. Role of cytochromes P450 in drug metabolism and hepatotoxicity
133. Cloning of DNA complementary to cytochrome P-450 induced by pregnenolone-16a-carbon-itrile
134. Pregnenolone 16a-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation
135. Immunochemical evidence for multiple steroid-inducible hepatic cytochromes P-450 in the rat
136. Evidence for functional and structural multiplicity of pregnenolone-16a-carbonitrile-inducible cytochrome P-450 isozymes in rat liver microsomes
137. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes
138. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p
139. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450
140. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes
141. Identification of an inducible form of cytochrome P-450 in human liver
142. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
143. Monoclonal antibodies against human liver cytochrome P-450
144. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver
145. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase
146. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase
147. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity
148. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 66-hydroxylase cytochrome P-450 enzyme
149. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16ot-hydroxylase of dehydroepiandrosterone 3-sulfate
150. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5, bis(alkoxycarbonyl)-l, 4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450
151. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporin with other drugs
152. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s
153. Bioactivation of aflatoxin B, by human liver microsomes: role of cytochrome P450 IIIA enzymes
154. Oxidation of quinidine by human liver cytochrome P-450
155. Oxidation of 17a-ethynylestra-diol by human liver cytochrome P-450
156. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
157. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid se-necionine in human liver
158. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
159. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
160. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450
161. 6b˜-Hy-droxycortisol: a noninvasive indicator of enzyme induction
162. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis
163. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)
164. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver
165. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver
166. Drugs and fetal metabolism
167. Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P-450
168. Identification of a cytochrome P-450 in human fetal liver related to glucorcorticoid-inducible cytochrome P-450HLp in the adult
169. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family
170. Purification and properties of cytochrome P-450 from homogenates of human fetal livers
171. Occurrence and inducibility of cytochrome P450IIIA in maternal and fetal rats during prenatal development
172. Four forms of cytochrome P-450 in human fetal liver: purification and their capacity to activate promutagens.y
173. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin